Jessica Saenz
Physician Assistant · San Juan, TXNPI 1265763874
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 308 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,496 and has fallen 56.3% since, to $654 in 2025. Among physician assistant clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$811
- AstraZeneca$810
- Novo Nordisk$662
- GSK$505
- Amgen$331
- Kowa Pharmaceuticals America, Inc.$275
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,96999%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 71 | $811 |
| AstraZeneca | 43 | $810 |
| Novo Nordisk | 37 | $662 |
| GSK | 30 | $505 |
| Amgen | 18 | $331 |
| Kowa Pharmaceuticals America, Inc. | 24 | $275 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $195 |
| Pfizer | 9 | $164 |
| Amarin Pharma, Inc. | 8 | $147 |
| Boehringer Ingelheim | 7 | $143 |
| Johnson & Johnson | 6 | $135 |
| Exact Sciences | 6 | $113 |
| Bayer | 5 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $97 |
| AbbVie | 4 | $81 |
| Sobi, Inc | 3 | $73 |
| Otsuka America Pharmaceutical, Inc. | 2 | $56 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $49 |
| Merck | 3 | $41 |
| Astellas Pharma US Inc | 3 | $38 |
| Corcept Therapeutics | 1 | $28 |
| Dexcom, Inc. | 1 | $20 |
| Averitas Pharma Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Redhill Biopharma Inc. | 1 | $16 |
| Ardelyx, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Novartis | 1 | $14 |
How this compares
$5,018 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $49,164 |
| JardianceEmpagliflozin | 42 | $42,175 |
| MounjaroTirzepatide | 28 | $33,313 |
| TrulicityDulaglutide | 15 | $21,215 |
| XareltoRivaroxaban | 17 | $18,488 |
| TradjentaLinagliptin | 13 | $17,982 |
| MyrbetriqMirabegron | 24 | $14,907 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $13,331 |
| TrintellixVortioxetine Hydrobromide | 22 | $12,666 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $9,865 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,768 |
| VascepaIcosapent Ethyl | 14 | $8,746 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $4,163 |
| Icosapent Ethyl | 12 | $3,498 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $143 | $60,15755 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $811 | $55,26454 claims |
| Novo NordiskOzempic | $662 | $49,16442 claims |
| Johnson & JohnsonXarelto | $135 | $18,48817 claims |
| Astellas Pharma US IncMyrbetriq | $38 | $14,90724 claims |
| GSKTrelegy Ellipta | $505 | $13,33118 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $97 | $12,66622 claims |
| AstraZenecaBreztri Aerosphere | $810 | $8,76813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in San Juan
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
- Michael WhiteDallas$276K
- Heidi JeffreysLubbock$259K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.